JP2018528162A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018528162A5 JP2018528162A5 JP2017568292A JP2017568292A JP2018528162A5 JP 2018528162 A5 JP2018528162 A5 JP 2018528162A5 JP 2017568292 A JP2017568292 A JP 2017568292A JP 2017568292 A JP2017568292 A JP 2017568292A JP 2018528162 A5 JP2018528162 A5 JP 2018528162A5
- Authority
- JP
- Japan
- Prior art keywords
- carbon atoms
- optionally substituted
- branched
- alkyl
- alkynyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CC(C)(CSC(CC(N1CCNC(CCCSS[C@](C)(*)CCC(Nc2cc(COc(c(OC)c3)cc(NC[C@]4N5c6ccccc6C4)c3C5=O)cc(COc(cc(c(C(N(CC3)c4c3cccc4)=O)c3)N=*)c3OC)c2)=O)=O)=O)C1=O)C#C Chemical compound CC(C)(CSC(CC(N1CCNC(CCCSS[C@](C)(*)CCC(Nc2cc(COc(c(OC)c3)cc(NC[C@]4N5c6ccccc6C4)c3C5=O)cc(COc(cc(c(C(N(CC3)c4c3cccc4)=O)c3)N=*)c3OC)c2)=O)=O)=O)C1=O)C#C 0.000 description 8
- IWSKMCBAKLPXKV-UHFFFAOYSA-N CCC(CC(N1CCCC(NCC(NCC(NCC(NCCC(NCCN(C(CC2C)=O)C2=O)=O)=O)=O)=O)=O)=O)C1=O Chemical compound CCC(CC(N1CCCC(NCC(NCC(NCC(NCCC(NCCN(C(CC2C)=O)C2=O)=O)=O)=O)=O)=O)=O)C1=O IWSKMCBAKLPXKV-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562186254P | 2015-06-29 | 2015-06-29 | |
| US62/186,254 | 2015-06-29 | ||
| US201662338245P | 2016-05-18 | 2016-05-18 | |
| US62/338,245 | 2016-05-18 | ||
| PCT/US2016/039796 WO2017004025A1 (en) | 2015-06-29 | 2016-06-28 | Conjugates of cysteine engineered antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021025322A Division JP2021088581A (ja) | 2015-06-29 | 2021-02-19 | システイン改変抗体の複合体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018528162A JP2018528162A (ja) | 2018-09-27 |
| JP2018528162A5 true JP2018528162A5 (OSRAM) | 2019-08-08 |
| JP6843080B2 JP6843080B2 (ja) | 2021-03-17 |
Family
ID=56409216
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017568292A Active JP6843080B2 (ja) | 2015-06-29 | 2016-06-28 | システイン改変抗体の複合体 |
| JP2021025322A Pending JP2021088581A (ja) | 2015-06-29 | 2021-02-19 | システイン改変抗体の複合体 |
| JP2022129205A Active JP7441281B2 (ja) | 2015-06-29 | 2022-08-15 | システイン改変抗体の複合体 |
| JP2024021646A Pending JP2024067036A (ja) | 2015-06-29 | 2024-02-16 | システイン改変抗体の複合体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021025322A Pending JP2021088581A (ja) | 2015-06-29 | 2021-02-19 | システイン改変抗体の複合体 |
| JP2022129205A Active JP7441281B2 (ja) | 2015-06-29 | 2022-08-15 | システイン改変抗体の複合体 |
| JP2024021646A Pending JP2024067036A (ja) | 2015-06-29 | 2024-02-16 | システイン改変抗体の複合体 |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US10898579B2 (OSRAM) |
| EP (2) | EP3769787A1 (OSRAM) |
| JP (4) | JP6843080B2 (OSRAM) |
| KR (1) | KR102793098B1 (OSRAM) |
| CN (2) | CN113769108B (OSRAM) |
| AR (1) | AR106013A1 (OSRAM) |
| AU (2) | AU2016285929B2 (OSRAM) |
| CA (1) | CA2988806C (OSRAM) |
| CY (1) | CY1123606T1 (OSRAM) |
| DK (1) | DK3313845T3 (OSRAM) |
| ES (1) | ES2832527T3 (OSRAM) |
| HR (1) | HRP20201790T1 (OSRAM) |
| HU (1) | HUE052616T2 (OSRAM) |
| LT (1) | LT3313845T (OSRAM) |
| MA (1) | MA42250B1 (OSRAM) |
| MD (1) | MD3313845T2 (OSRAM) |
| PL (1) | PL3313845T3 (OSRAM) |
| PT (1) | PT3313845T (OSRAM) |
| RS (1) | RS61050B1 (OSRAM) |
| RU (1) | RU2733740C2 (OSRAM) |
| SI (1) | SI3313845T1 (OSRAM) |
| SM (1) | SMT202000614T1 (OSRAM) |
| TW (2) | TWI740833B (OSRAM) |
| WO (1) | WO2017004025A1 (OSRAM) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114672490A (zh) | 2015-06-29 | 2022-06-28 | 伊缪诺金公司 | 抗cd123抗体以及其缀合物和衍生物 |
| JP2019501139A (ja) | 2015-11-25 | 2019-01-17 | イミュノジェン・インコーポレーテッド | 医薬製剤及びその使用 |
| CN116813690A (zh) | 2016-11-23 | 2023-09-29 | 伊缪诺金公司 | 苯并二氮䓬衍生物的选择性磺化 |
| TWI783957B (zh) | 2016-12-23 | 2022-11-21 | 美商伊繆諾金公司 | 靶向adam9之免疫共軛物及其使用方法 |
| WO2018183494A1 (en) | 2017-03-31 | 2018-10-04 | Immunogen, Inc. | Cd19-targeting antibody-drug conjugates |
| MA50195A (fr) * | 2017-09-22 | 2020-07-29 | Immunogen Inc | Séparation d'anticorps à chaîne triple légère à l'aide d'une chromatographie à échange de cations |
| CN117003875A (zh) | 2017-09-29 | 2023-11-07 | 第一三共株式会社 | 抗体或其功能性片段、多核苷酸、表达载体、宿主细胞、糖链重构抗体、药物组合物、应用 |
| TWI897855B (zh) | 2018-10-26 | 2025-09-21 | 美商免疫遺傳股份有限公司 | Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途 |
| AU2019370291A1 (en) | 2018-10-30 | 2021-05-20 | Immunogen, Inc. | Methods of treatment using anti-CD123 immunoconjugates |
| KR20210098470A (ko) * | 2018-11-12 | 2021-08-10 | 이뮤노젠 아이엔씨 | 세포독성 벤조디아제핀 유도체의 제조 방법 |
| SG11202104423XA (en) * | 2018-11-12 | 2021-05-28 | Immunogen Inc | Methods of preparing cytotoxic benzodiazepine derivatives |
| JP7401456B2 (ja) | 2018-11-14 | 2023-12-19 | 第一三共株式会社 | 抗ｃｄｈ６抗体－ピロロベンゾジアゼピン誘導体コンジュゲート |
| CN113631194A (zh) * | 2019-03-21 | 2021-11-09 | 伊缪诺金公司 | 制备细胞结合剂-药物缀合物的方法 |
| TWI856078B (zh) | 2019-03-25 | 2024-09-21 | 日商第一三共股份有限公司 | 抗體–吡咯并苯二氮呯衍生物結合物、其製造方法及其用途 |
| KR20210141630A (ko) | 2019-03-25 | 2021-11-23 | 다이이찌 산쿄 가부시키가이샤 | 항 her2 항체-피롤로벤조디아제핀 유도체 콘주게이트 |
| CA3139180A1 (en) | 2019-03-27 | 2020-10-01 | Daiichi Sankyo Company, Limited | Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor |
| EP3962528A4 (en) | 2019-04-29 | 2023-01-11 | Immunogen, Inc. | Therapeutic combinations comprising anti-cd123 immunoconjugates |
| TW202227479A (zh) | 2020-09-02 | 2022-07-16 | 日商第一三共股份有限公司 | 新穎內－β－Ｎ－乙醯葡萄糖胺苷酶 |
| AU2022207708A1 (en) | 2021-01-13 | 2023-07-27 | Daiichi Sankyo Company, Limited | Antibody-pyrrolobenzodiazepine derivative conjugate |
| KR20240113514A (ko) | 2021-11-30 | 2024-07-22 | 다이이찌 산쿄 가부시키가이샤 | 프로테아제 분해성 마스크 항체 |
| JPWO2023153442A1 (OSRAM) | 2022-02-09 | 2023-08-17 | ||
| EP4488378A1 (en) | 2022-03-02 | 2025-01-08 | Daiichi Sankyo Company, Limited | Method for producing fc-containing molecule |
| WO2025235924A2 (en) | 2024-05-10 | 2025-11-13 | Immunogen, Inc. | Anti-cd123 immunoconjugates for the treatment of acute myeloid leukemia |
| US20250345449A1 (en) | 2024-05-10 | 2025-11-13 | Immunogen, Inc. | Anti-cd123 immunoconjugates for the treatment of blastic plasmacytoid cell neoplasm |
| WO2025250969A1 (en) | 2024-05-31 | 2025-12-04 | Vertex Pharmaceuticals Incorporated | Anti-cd74 antibodies, conjugates and uses thereof |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| DE69231123T2 (de) | 1992-03-25 | 2001-02-15 | Immunogen Inc | Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065 |
| GB9422383D0 (en) * | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
| PT1242401E (pt) | 1999-11-24 | 2007-03-30 | Immunogen Inc | Agentes citotóxicos compreendendo taxanos e o seu uso terapêutico |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US6716821B2 (en) | 2001-12-21 | 2004-04-06 | Immunogen Inc. | Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same |
| US6756397B2 (en) | 2002-04-05 | 2004-06-29 | Immunogen, Inc. | Prodrugs of CC-1065 analogs |
| US20050276812A1 (en) | 2004-06-01 | 2005-12-15 | Genentech, Inc. | Antibody-drug conjugates and methods |
| CA2494074A1 (en) | 2002-08-02 | 2004-02-12 | Immunogen, Inc. | Cytotoxic agents containing novel potent taxanes and their therapeutic use |
| CA2495795C (en) | 2002-08-16 | 2011-12-13 | Immunogen, Inc. | Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs |
| CA2504818C (en) | 2002-11-07 | 2013-04-23 | Immunogen, Inc. | Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same |
| CN101239190B (zh) * | 2003-01-27 | 2013-09-25 | 恩多塞特公司 | 维生素受体结合递药缀合物 |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| US7276497B2 (en) | 2003-05-20 | 2007-10-02 | Immunogen Inc. | Cytotoxic agents comprising new maytansinoids |
| WO2005084390A2 (en) | 2004-03-02 | 2005-09-15 | Seattle Genetics, Inc. | Partially loaded antibodies and methods of their conjugation |
| TR201808537T4 (tr) | 2004-09-23 | 2018-07-23 | Genentech Inc | Sistein değiştirilmiş antikorlar ve konjugatlar. |
| JP2008521828A (ja) | 2004-11-29 | 2008-06-26 | シアトル ジェネティックス， インコーポレイテッド | 操作された抗体およびイムノコンジュゲート |
| US8008453B2 (en) | 2005-08-12 | 2011-08-30 | Amgen Inc. | Modified Fc molecules |
| RS54163B1 (sr) | 2006-05-30 | 2015-12-31 | Genentech Inc. | Anti-cd22 antitela, njihovi imunokonjugati i njihova upotreba |
| CA2681974C (en) | 2007-03-29 | 2019-12-31 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| BRPI0911442A2 (pt) | 2008-04-30 | 2019-03-12 | Immunogen, Inc. | conjugados potentes e ligantes hidrofílicos |
| KR101764927B1 (ko) | 2008-04-30 | 2017-08-03 | 이뮤노젠 아이엔씨 | 가교제 및 그 용도 |
| CN108727407B (zh) * | 2009-02-05 | 2022-01-28 | 伊缪诺金公司 | 新型苯并二氮杂䓬衍生物 |
| US8431416B2 (en) * | 2009-04-01 | 2013-04-30 | Becton, Dickinson And Company | Reactive heterocycle-substituted 7-hydroxycoumarins and their conjugates |
| AU2010270979B2 (en) | 2009-06-22 | 2015-04-23 | Medimmune, Llc | Engineered Fc regions for site-specific conjugation |
| WO2011092838A1 (ja) | 2010-01-29 | 2011-08-04 | 株式会社フォーサイド・ドット・コム | コンテンツ共有システム、およびコンテンツ共有方法 |
| TWI796132B (zh) | 2010-02-24 | 2023-03-11 | 美商免疫遺傳股份有限公司 | 葉酸受體１抗體類和免疫共軛物類及彼等之用途 |
| SMT201900549T1 (it) | 2010-03-12 | 2019-11-13 | Debiopharm Int Sa | Molecole leganti il cd37 e loro immunoconiugati |
| PL2560993T3 (pl) | 2010-04-20 | 2024-11-04 | Genmab A/S | Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania |
| AU2011320318B9 (en) | 2010-10-29 | 2015-11-19 | Immunogen, Inc. | Non-antagonistic EGFR-binding molecules and immunoconjugates thereof |
| AU2011320314B2 (en) | 2010-10-29 | 2015-08-06 | Immunogen, Inc. | Novel EGFR-binding molecules and immunoconjugates thereof |
| WO2012112708A1 (en) * | 2011-02-15 | 2012-08-23 | Immunogen, Inc. | Cytotoxic benzodiazepine derivatives and methods of preparation |
| WO2013177481A1 (en) * | 2012-05-25 | 2013-11-28 | Immunogen, Inc. | Benzodiazepines and conjugates thereof |
| US9901647B2 (en) | 2013-02-28 | 2018-02-27 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| WO2014134483A2 (en) * | 2013-02-28 | 2014-09-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| WO2014134457A2 (en) | 2013-02-28 | 2014-09-04 | Immunogen, Inc. | Conjugates comprising cell-binding agents and cytotoxic agents |
| CN106459205B (zh) * | 2014-04-11 | 2021-04-09 | 免疫医疗有限责任公司 | 包含半胱氨酸工程化抗体的轭合化合物 |
| SG10201811124YA (en) * | 2014-06-20 | 2019-01-30 | Abgenomics Int Inc | Her2 antibody-drug conjugates |
| CA2952876A1 (en) * | 2014-06-20 | 2015-12-23 | Bioalliance C.V. | Anti-folate receptor alpha (fra) antibody-drug conjugates and methods of using thereof |
| JP2017523958A (ja) | 2014-06-20 | 2017-08-24 | バイオアライアンス コマンディテール フェンノートシャップ | 抗ｃｄ２２抗体−薬物コンジュゲート及びその使用方法 |
| CN109147874A (zh) | 2014-09-02 | 2019-01-04 | 伊缪诺金公司 | 用于配制抗体药物缀合物组合物的方法 |
| MA41645A (fr) | 2015-03-04 | 2018-01-09 | Abbvie Stemcentrx Llc | Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation |
| CN114672490A (zh) | 2015-06-29 | 2022-06-28 | 伊缪诺金公司 | 抗cd123抗体以及其缀合物和衍生物 |
| CN116813690A (zh) * | 2016-11-23 | 2023-09-29 | 伊缪诺金公司 | 苯并二氮䓬衍生物的选择性磺化 |
-
2016
- 2016-06-28 LT LTEP16738322.3T patent/LT3313845T/lt unknown
- 2016-06-28 HU HUE16738322A patent/HUE052616T2/hu unknown
- 2016-06-28 ES ES16738322T patent/ES2832527T3/es active Active
- 2016-06-28 JP JP2017568292A patent/JP6843080B2/ja active Active
- 2016-06-28 MA MA42250A patent/MA42250B1/fr unknown
- 2016-06-28 RS RS20201354A patent/RS61050B1/sr unknown
- 2016-06-28 PL PL16738322T patent/PL3313845T3/pl unknown
- 2016-06-28 EP EP20182141.0A patent/EP3769787A1/en active Pending
- 2016-06-28 US US15/195,269 patent/US10898579B2/en active Active
- 2016-06-28 SM SM20200614T patent/SMT202000614T1/it unknown
- 2016-06-28 CA CA2988806A patent/CA2988806C/en active Active
- 2016-06-28 RU RU2017144859A patent/RU2733740C2/ru active
- 2016-06-28 AU AU2016285929A patent/AU2016285929B2/en active Active
- 2016-06-28 SI SI201630977T patent/SI3313845T1/sl unknown
- 2016-06-28 EP EP16738322.3A patent/EP3313845B1/en active Active
- 2016-06-28 CN CN202111168673.4A patent/CN113769108B/zh active Active
- 2016-06-28 CN CN201680038492.0A patent/CN107708810B/zh active Active
- 2016-06-28 HR HRP20201790TT patent/HRP20201790T1/hr unknown
- 2016-06-28 WO PCT/US2016/039796 patent/WO2017004025A1/en not_active Ceased
- 2016-06-28 DK DK16738322.3T patent/DK3313845T3/da active
- 2016-06-28 KR KR1020187002729A patent/KR102793098B1/ko active Active
- 2016-06-28 MD MDE20180452T patent/MD3313845T2/ro unknown
- 2016-06-28 PT PT167383223T patent/PT3313845T/pt unknown
- 2016-06-29 AR ARP160101972A patent/AR106013A1/es active IP Right Grant
- 2016-06-29 TW TW105120514A patent/TWI740833B/zh active
- 2016-06-29 TW TW110132303A patent/TWI880021B/zh active
-
2020
- 2020-09-08 US US17/014,404 patent/US20210085800A1/en not_active Abandoned
- 2020-11-10 CY CY20201101058T patent/CY1123606T1/el unknown
-
2021
- 2021-02-19 JP JP2021025322A patent/JP2021088581A/ja active Pending
-
2022
- 2022-03-31 AU AU2022202208A patent/AU2022202208B2/en active Active
- 2022-08-15 JP JP2022129205A patent/JP7441281B2/ja active Active
-
2024
- 2024-02-16 JP JP2024021646A patent/JP2024067036A/ja active Pending
- 2024-06-11 US US18/739,709 patent/US20250011340A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018528162A5 (OSRAM) | ||
| RU2017144859A (ru) | Конъюгаты сконструированных антител с цистеиновыми заменами | |
| CN119306732B (zh) | 生物活性物偶联物及其制备方法和用途 | |
| EP2968593B1 (en) | Biologically active molecules, conjugates thereof, and therapeutic uses | |
| EP3327027B1 (en) | Cytotoxic peptides and antibody drug conjugates thereof | |
| JP2017529837A5 (OSRAM) | ||
| AU2022204711B9 (en) | Peptidic linkers and cryptophycin conjugates, useful in therapy, and their preparation | |
| EP2790731A2 (de) | Fgfr-binder-wirkstoff konjugate und ihre verwendung | |
| EP3501546A2 (de) | Cystein-wirkstoff konjugate und ihre verwendung | |
| US20090105200A1 (en) | Combination therapy | |
| EP3408271A1 (en) | Maytansinoid derivatives, conjugates thereof, and methods of use | |
| AU2018368520B2 (en) | Ligand-drug-conjugates as substrates for selective cleavage by the exopeptidase activity of Cathepsin B | |
| JP2018016629A (ja) | 固形腫瘍を治療するためのｆａｐ活性化プロテアソーム阻害剤 | |
| JP2017514905A5 (OSRAM) | ||
| JP2018528261A (ja) | グルタミン類似体のプロドラッグ | |
| CA3003085A1 (en) | Cryptophycin compounds and conjugates, their preparation and their therapeutic use | |
| US20010056178A1 (en) | Deoxo-proline-containing tamandarin and didemnin analogs, dehydro-proline-containing tamandarin and didemnin analogs, and methods of making and using them | |
| JP2016510730A5 (OSRAM) | ||
| TW202515620A (zh) | 抗體－藥物偶聯物靶向治療前列腺癌和其他腫瘤 | |
| KR20250163875A (ko) | 핵 위치화 폴리펩타이드 및 컨주게이트 및 이의 용도 | |
| HK40085405A (en) | Method for producing antibody-drug conjugate | |
| EA045708B1 (ru) | Новые пептидные линкеры и конъюгаты на основе криптофицина, их получение и их терапевтическое применение | |
| EA046139B1 (ru) | Конъюгаты лиганда-лекарственного средства в качестве субстратов для селективного расщепления под действием экзопептидазной активности катепсина b | |
| HK1212890B (en) | Biologically active molecules, conjugates thereof, and therapeutic uses | |
| HK40066743A (en) | Biologically active molecules, conjugates thereof, and therapeutic uses |